LobbyingHorizon Therapeutics lobbying by quarter
Horizon Therapeutics's latest lobbying report covers Q4 2023, at $60K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Horizon Therapeutics
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $60K | 1 |
| Q1 2023 | $60K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $60K | 1 |
| Q4 2023 | $60K | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Health issues5 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES5 reports
- SENATE5 reports
Firms it paid
| Firm | ||
|---|---|---|
| Gray Global Advisors | $300K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| EDOLPHUS TOWNS | Former Member of Congress 1983-2013 | Q4 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/01/19for Q4 2023 | Gray Global Advisors | $60K |
| 23/10/20for Q3 2023 | Gray Global Advisors | $60K |
| 23/07/19for Q2 2023 | Gray Global Advisors | $60K |
| 23/04/20for Q1 2023 | Gray Global Advisors | $60K |
| 23/04/20for Q1 2023 | Gray Global Advisors | Under $5,000 |
| 23/01/20for Q4 2022 | Gray Global Advisors | $60K |
| 23/01/20for Q4 2022 | Gray Global Advisors | $60K |